Appointment expands the company’s leadership expertise as Fluid Biomed advances development of its polymer-based stent technology to treat brain aneurysms and stroke.
John Kilcoyne joins Fluid Biomed as its Independent Board Chair. Mr. Kilcoyne has led a distinguished 40-plus-year career in the medical device industry at both the Board and Executive levels. During this period, he has demonstrated exceptional leadership and built success-oriented cultures. He has successfully led multiple organizations through reorganizations, acquisitions, startups, and public offerings. He was the CEO of Endonetics, from 1997 until its acquisition by Medtronic in 2002. From 2002 to 2004, John served as the CEO of Solace Therapeutics. From 2004 until 2010, he was President and CEO at Micrus Endovascular Corporation, leading its IPO efforts in 2005, capturing significant market share and acquisition by Johnson & Johnson in 2010. He is currently the CEO of JenaValve, a company innovating in the cardiac valve space. As a result of his leadership, Mr. Kilcoyne has been responsible for the creation of more than $1 billion in value through a combination of initial public offerings and acquisitions.